Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs GRF-6019 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Alkahest
  • Most Recent Events

    • 29 Oct 2018 According Alkahest media release, data from this trial was presented at the Clinical Trials in Alzheimer's Disease (CTAD) Conference in Barcelona on 26th October.
    • 26 Jul 2018 Trial design presented at the Alzheimer's Association International Conference 2018
    • 23 Jul 2018 According Alkahest media release, data from this syudy will be preasented at Alzheimers Association International Conference (AAIC) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top